GlassScriptPhysician profile
Ashley Cawa
NPI 1043999204
$1,487.63
in general payments reported to CMS, 2019-2025
13 companies · $510 in 2025
The $510 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $253 · 2024: $724 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $291.54 | 2023-2025 | |
| Astellas Pharma US INC | $212.80 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $209.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $206.73 | 2023-2025 | |
| Novo Nordisk INC | $195.85 | 2024-2025 | Wegovy, Saxenda |
| Acella Pharmaceuticals, LLC | $79.08 | 2023-2025 | NP Thyroid 60 |
| Idorsia Pharmaceuticals US INC | $63.31 | 2023-2024 | Quviviq |
| Exeltis, USA INC. | $53.09 | 2023-2025 | Slynd, Nuvessa |
| Shield Therapeutics INC | $45.18 | 2023-2024 | Accrufer |
| Mayne Pharma Commercial LLC | $43.41 | 2024 | |
| Organon LLC | $39.10 | 2023-2024 | Nexplanon |
| Millicent US INC | $31.84 | 2025 | Femlyv, Intrarosa |
| Axsome Therapeutics, INC. | $16.25 | 2025 | Symbravo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Cawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.